HRT Financial LLC Takes $52,000 Position in Amyris Inc (AMRS)

HRT Financial LLC purchased a new position in shares of Amyris Inc (NASDAQ:AMRS) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 15,812 shares of the biotechnology company’s stock, valued at approximately $52,000.

A number of other large investors have also recently made changes to their positions in AMRS. Jane Street Group LLC acquired a new stake in Amyris during the 4th quarter valued at $48,000. Caption Management LLC acquired a new position in shares of Amyris in the fourth quarter worth about $50,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Amyris in the fourth quarter worth about $58,000. Intellectus Partners LLC boosted its holdings in shares of Amyris by 263.6% in the fourth quarter. Intellectus Partners LLC now owns 20,000 shares of the biotechnology company’s stock worth $67,000 after buying an additional 14,500 shares during the period. Finally, Balasa Dinverno & Foltz LLC boosted its holdings in shares of Amyris by 99.6% in the fourth quarter. Balasa Dinverno & Foltz LLC now owns 23,711 shares of the biotechnology company’s stock worth $79,000 after buying an additional 11,834 shares during the period. 36.69% of the stock is owned by hedge funds and other institutional investors.

In other news, Director L John Doerr purchased 2,832,440 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were bought at an average price of $5.12 per share, with a total value of $14,502,092.80. Following the completion of the transaction, the director now directly owns 5,532 shares in the company, valued at approximately $28,323.84. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 21.80% of the company’s stock.

Several analysts recently commented on the stock. BidaskClub upgraded shares of Amyris from a “sell” rating to a “hold” rating in a report on Thursday, April 18th. Zacks Investment Research upgraded shares of Amyris from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 15th. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Amyris in a report on Monday, December 31st. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Amyris has an average rating of “Buy” and a consensus price target of $8.83.

Shares of AMRS stock traded down $0.11 during trading on Friday, hitting $4.75. 1,786,900 shares of the company were exchanged, compared to its average volume of 3,703,752. The stock has a market cap of $391.81 million, a P/E ratio of -1.88 and a beta of 0.29. Amyris Inc has a twelve month low of $1.87 and a twelve month high of $9.28.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($1.07) EPS for the quarter, missing the consensus estimate of $0.44 by ($1.51). The company had revenue of $19.36 million for the quarter, compared to analyst estimates of $98.52 million. The business’s revenue for the quarter was down 76.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.61 EPS. On average, analysts predict that Amyris Inc will post -0.31 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “HRT Financial LLC Takes $52,000 Position in Amyris Inc (AMRS)” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/hrt-financial-llc-takes-position-in-amyris-inc-amrs.html.

Amyris Company Profile

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Featured Article: Debt-To-Equity Ratio

Institutional Ownership by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.